


5

Patent claims

1. A pharmaceutical agent for treatment of neuropathies, characterized in that it consists, at least in part, of a compound of formula (I):



in which:

$R^1 = C_{1-6}$ alkyl, optionally substituted with halogen,

$R^2 =$ hydrogen or C_{1-4} alkyl, optionally substituted by halogen or replaced with halogen,

$R^3 = C_{2-4}$ alkyl, optionally substituted with halogen,

$R^4 = SO_2NR^5R^6$,

C_{1-4} alkyl, optionally substituted with NR^5R^6 ,

CN, $CONR^5R^6$, CO_2R^7 , or halogen,

C_{2-4} -alkenyl, possibly substituted with

NR^5R^6 , $SONR^5R^6$, $CONR^5R^6$, CO_2R^7 , or halogen,

C_{2-4} -alkanoyl, optionally substituted with

NR^5R^6 , $SONR^5R^6$, $CONR^5R^6$, CO_2R^7 , or halogen,


R^5 and R^6 , independent of one another, represent hydrogen or C_{1-4} alkyl, or, together with the nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, 4-(NR^8)-1-piperazinyl or 1-imidazolyl ring which, optionally, may be substituted with one or

two C_{1-4} alkyl groups,

$R^7 =$ hydrogen, C_{1-4} alkyl, optionally, are substituted with fluorine, and


$R^8 =$ hydrogen, C_{1-3} alkyl, or hydroxy alkyl with 1 - 4 C atoms; or of a pharmaceutically acceptable salt of such a compound.

- 5 2. The pharmaceutical agent according to Claim 1, characterized in that it consists, at least in part, of a compound of formula (Ia):



- in which the groups R¹ to R³ have the meaning specified in Claim 1, and R⁹ is an alkyl group having 1 - 4 C atoms which, optionally, are substituted or replaced by halogen; or of a
10 pharmaceutically acceptable salt of such a compound.


3. The pharmaceutical agent according to Claim 1, characterized in that it consists, at least in part, of a compound of formula (III):



15

- or of a pharmaceutically acceptable salt of such a compound.

- 5 4. A use of compounds of formula (I):



in which

R^1 = C_{1-6} alkyl, optionally substituted with halogen,

10 R^2 = hydrogen or C_{1-4} alkyl, optionally substituted with halogen or replaced with halogen,

R^3 = C_{2-4} alkyl, optionally substituted with halogen,

R^4 = $SO_2NR^5R^6$,

C_{1-4} alkyl, optionally substituted with NR^5R^6 ,

CN, $CONR^5R^6$, CO_2R^7 , or halogen,

15 C_{2-4} -alkenyl, optionally substituted with

NR^5R^6 , $SONR^5R^6$, $CONR^5R^6$, CO_2R^7 , or halogen,

C_{2-4} -alkanoyl, optionally substituted with


NR^5R^6 , $SONR^5R^6$, $CONR^5R^6$, CO_2R^7 , or halogen,

20 R^5 and R^6 , independent of one another, represent hydrogen or C_{1-4} alkyl, or, together with the nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, 4-(NR^8)-1-piperazinyl or 1-imidazolyl ring which, optionally, may be substituted with one or two C_{1-4} alkyl groups,

R^7 = hydrogen or C_{1-4} alkyl, optionally, substituted with fluorine, and

25 R^8 = hydrogen, C_{1-3} alkyl, or hydroxy alkyl with 1 - 4 C atoms, or of a pharmaceutically acceptable salt of such a compound for production of a pharmaceutical agent for treatment of neuropathies.

- 5 5. A chemotherapeutic method for treatment of neuropathies characterized by application to a patient of a pharmaceutical agent which consists, at least in part, of a compound of formula (I):



in which

- 10 $R^1 = C_{1-6}$ alkyl, optionally substituted with halogen,
 $R^2 =$ hydrogen or C_{1-4} alkyl, optionally substituted with halogen or replaced with halogen,
 $R^3 = C_{2-4}$ alkyl, optionally substituted with halogen,
 $R^4 = SO_2NR^5R^6$,
 C_{1-4} alkyl, optionally substituted with NR^5R^6 ,
 15 CN , $CONR^5R^6$, CO_2R^7 , or halogen,
 C_{2-4} -alkenyl, optionally substituted with
 NR^5R^6 , $SONR^5R^6$, $CONR^5R^6$, CO_2R^7 , or halogen,
 C_{2-4} -alkanoyl, optionally substituted with
 NR^5R^6 , $SONR^5R^6$, $CONR^5R^6$, CO_2R^7 , or halogen,
 20 R^5 and R^6 , independent of one another, represent hydrogen or C_{1-4} alkyl, or, together with the nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, 4-(NR^8)-1-piperazinyl or 1-imidazolyl ring which, optionally, may be substituted with one or two C_{1-4} alkyl groups,
 $R^7 =$ hydrogen or C_{1-4} alkyl, optionally, substituted with fluorine, and
 25 $R^8 =$ hydrogen, C_{1-3} alkyl, or hydroxy alkyl having 1 - 4 C atoms, or of a pharmaceutically acceptable salt of such a compound.